ArticleAsian journal of transfusion science
Blood component utilization in hospitalized COVID-19 patients: Experience from a dedicated COVID-19 center.
Article in Asian journal of transfusion science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood transfusion services were seriously affected during COVID-19 not only due to limited availability of blood components but also due to gap in the clinical knowledge about the need for transfusion in COVID-19 patients. However, understanding the transfusion needs is essential for inventory management. We analyzed the utilization of blood components in hospitalized COVID-19 patients and recorded the outcome of the patients who were transfused. MATERIALS AND
methodsThe study included all COVID-19 patients who underwent transfusions over a time period. Patient details included demographics, clinical condition, comorbidities, laboratory parameters, and outcome. Details of transfusion were collected from the blood bank and patient records.
resultsOf 3052 hospitalized COVID-19 patients, 395 (12.9%) were transfused blood components and were included in the study. Comorbidities were identified in 85% of these patients. Red blood cell (RBC) was transfused in 348 (11.4%) with a mean of 2.3 units/patient. Similarly, platelets and fresh frozen plasma were transfused in 3.3% of patients (mean 6.2 units) and 3% (mean 4.9 units), respectively. Transfusion triggers were largely restrictive in nature. Patients with haemato-oncologic conditions required significantly higher numbers of RBCs and random donor platelets. RBCs transfusion were also higher in patients requiring intensive care unit care and ventilatory support. Blood components usage was not affected by severity of COVID-19 disease, comorbidity index, or coagulopathy.
conclusionBlood utilization in COVID-19 patients is typically low. Blood components were mainly required by patients with preexisting comorbidities, or those requiring critical care. RBCs were the predominant blood component transfused. Coagulopathy associated with COVID-19 did not necessitate transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.